Description of the medicine: Procarbazine (Procarbazin)
N-Isopropyl-para- (2-methylhydrazino-methyl) benzamide hydrochloride.
Synonyms: Natulan, Matulane, Natulan, Natulanar, Procarbazine.
The chemical structure has elements of similarity with nitrosomethylurea (see) and dacarbazine (see).
It is believed that the presence of a methylhydrazine group in procarbazine promotes the accumulation of the drug in tumor cells, self-oxidation, and intracellular formation of peroxide and hydroxide radicals, which essentially mimics the effect of ionizing radiation.
Procarbazine is used for malignant diseases of the lymphatic tissues: for lymphogranulomatosis (including generalized forms), lymphosarcoma, reticulosarcoma, chronic lymphocytic leukemia. The drug is often effective in cases resistant to chloroethylamine and vinblastine (see Rozevin.).
Assign inside, starting with 50 mg, with a gradual increase of 50 mg to a daily dose of 250 to 300 mg. The drug is given in 1 to 2 to 3 doses (300 mg in 3 divided doses) daily for 15 to 20 days or until the development of leukopenia and thrombocytopenia. With the onset of the effect, the dose is gradually reduced to a maintenance dose, usually 150 to 50 mg per day. The total dose per treatment course is usually 4 to 7 g.
Procarbazine can be prescribed in combination with other antitumor drugs.
When using the drug, nausea, vomiting, paresthesia, drowsiness, confusion, ataxia, allergic skin reactions, alopecia can be observed. Neurological symptoms can be aggravated with the simultaneous use of sleeping pills, antipsychotics, and other psychotropic drugs.
The drug can cause inhibition of hematopoiesis, primarily myelopoiesis and thrombocytopoiesis. Treatment should be under the control of a blood picture.
Release form: capsules on 0,05 g (50 mg).
Storage: List A.